Hjem › Ikke-muskulinvasiv blærecancer › North Carolina
Kliniske studier for Ikke-muskulinvasiv blærecancer i North Carolina
6 studier for Ikke-muskulinvasiv blærecancer søker deltakere på steder i North Carolina.
Byer i North Carolina
Offisiell studietekst (engelsk)
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- Duke Cancer Institute, Durham
- Associate Urologist of North Carolina, Raleigh
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06995677A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
- Biorepository and Precision Pathology Center (BRPC), Durham
- Duke Cancer Institute, Durham
- Substrate Services Core Research Support (SSCRS), Durham
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07206225A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
- Urology Specialists of the Carolinas PLLC Charlotte, Charlotte
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07309445FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT05614739LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- UNC Chapel Hill Hospital, Chapel Hill
- Duke Health - Duke Cancer Center, Durham
- Associated Urologists of North Carolina, Raleigh
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT04752722Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- University of North Carolina, Chapel Hill
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 31. jul. 2026 · NCT07225127Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.